AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
BioPharma DiveBen FidlerSeptember 29, 2026
The equity investment comes alongside a deal to test Summit s ivonescimab alongside potentially many AstraZeneca drugs but doesn t hand the pharmaceutical company any ownership rights.